ReviewInternational journal of nanomedicine2025
Engineering Biomimetic Nanoplatforms for Acute Lung Injury: From Mechanistic Insights to Translational Opportunities.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) remains a critical clinical challenge characterized by uncontrolled inflammation, oxidative stress, and immune dysregulation, with limited therapeutic options and high mortality. In recent years, biomimetic nanoplatforms-including those derived from cell membranes, extracellular vesicles (EVs), and hybrid biological interfaces-have emerged as transformative tools for ALI management. Unlike conventional nanocarriers, these systems reproduce natural intercellular communication and immune evasion mechanisms, thereby achieving precise lung targeting, sustained therapeutic delivery, and coordinated regulation of inflammation and tissue repair.This review provides a comprehensive and mechanistic overview of biomimetic nanoplatforms in ALI therapy, with an emphasis on membrane-derived, EV-based, and hybrid nanosystems. We further introduce less-explored biomimetic strategies, including protein-, bacterial-, and virus-inspired nanoparticles, to expand the conceptual framework of biological mimicry in pulmonary nanomedicine. Beyond summarizing progress, we critically discuss key translational barriers-immunogenicity, model fidelity, and large-scale manufacturing-and propose integrative solutions leveraging artificial intelligence, organ-on-chip technologies, and precision medicine approaches.By offering a unified perspective on the design, function, and translational roadmap of biomimetic nanotherapeutics, this review highlights how the integration of biology-inspired engineering and pulmonary pathophysiology could pave the way toward personalized and clinically viable nanomedicine for ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.